Evaxion Biotech A/S (NASDAQ:EVAX) Sees Large Growth in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 980,100 shares, a growth of 709.3% from the December 31st total of 121,100 shares. Based on an average daily volume of 335,500 shares, the short-interest ratio is presently 2.9 days.

Evaxion Biotech A/S Stock Down 27.2 %

EVAX stock traded down $1.63 during midday trading on Tuesday, reaching $4.37. 784,573 shares of the company’s stock traded hands, compared to its average volume of 3,850,732. Evaxion Biotech A/S has a 52 week low of $2.38 and a 52 week high of $36.90. The company has a market cap of $5.11 million, a price-to-earnings ratio of -3.01 and a beta of -0.23. The firm’s fifty day moving average price is $5.32 and its 200-day moving average price is $11.10. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its earnings results on Thursday, October 31st. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.40. The business had revenue of $3.02 million for the quarter, compared to the consensus estimate of $0.19 million. As a group, sell-side analysts forecast that Evaxion Biotech A/S will post -0.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.